<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Parkinson's Disease: The Shaking Palsy | Adi Desai</title>
    <meta name="description" content="From James Parkinson's 1817 essay to modern deep brain stimulation: understanding the neurodegenerative disease affecting millions.">
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>A</text></svg>">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Sora:wght@300;400;500;600&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../post.css">
</head>
<body id="top">
    <div class="noise"></div>

    <nav class="nav">
        <a href="../" class="nav-back">Blog</a>
        <a href="https://adidesai.org" class="logo">A</a>
        <div class="nav-right">
            <a href="../../">Home</a>
            <a href="../">Blog</a>
            <a href="../../#contact" class="nav-cta">Contact</a>
        </div>
    </nav>

    <header class="article-header">
        <div class="article-header-content">
            <a href="../" class="back-link">← Back to Blog</a>
            <div class="article-meta">
                <span class="article-date">January 8, 2025</span>
                <span class="article-reading">9 min read</span>
            </div>
            <h1 class="article-title">Parkinson's Disease: The Shaking Palsy</h1>
            <p class="article-subtitle">From James Parkinson's 1817 essay to modern deep brain stimulation: understanding the neurodegenerative disease that affects movement, mood, and mind.</p>
            <div class="article-tags">
                <span class="article-tag">Neurodegenerative</span>
            </div>
        </div>
    </header>

    <section class="key-stats">
        <div class="key-stats-content">
            <div class="key-stat">
                <div class="key-stat-value">10M+</div>
                <div class="key-stat-label">People affected worldwide</div>
            </div>
            <div class="key-stat">
                <div class="key-stat-value">60+</div>
                <div class="key-stat-label">Typical age of onset</div>
            </div>
            <div class="key-stat">
                <div class="key-stat-value">1817</div>
                <div class="key-stat-label">First described</div>
            </div>
            <div class="key-stat">
                <div class="key-stat-value">1960s</div>
                <div class="key-stat-label">Levodopa discovered</div>
            </div>
        </div>
    </section>

    <main class="article-content">
        <article class="article-body">
            <h2>What is Parkinson's Disease?</h2>
            <p><strong>Parkinson's disease (PD)</strong> is a progressive neurodegenerative disorder primarily affecting movement. It results from the death of dopamine-producing neurons in a brain region called the <strong>substantia nigra</strong>. By the time symptoms appear, 60-80% of these neurons have already been lost.<a href="#ref4" class="cite">[4]</a></p>

            <p>While known for tremor, Parkinson's is much more than a movement disorder. It affects mood, cognition, sleep, autonomic function, and quality of life in profound ways.</p>

            <div class="info-box">
                <div class="info-box-title">Cardinal Motor Symptoms</div>
                <ul>
                    <li><strong>Tremor:</strong> Resting tremor, often starting in one hand ("pill-rolling")</li>
                    <li><strong>Bradykinesia:</strong> Slowness of movement; the most disabling symptom</li>
                    <li><strong>Rigidity:</strong> Muscle stiffness; "cogwheel" resistance to passive movement</li>
                    <li><strong>Postural instability:</strong> Balance problems; develops later in disease</li>
                </ul>
            </div>

            <h2>Discovery: James Parkinson's Essay (1817)</h2>
            <p>In 1817, London physician <strong>James Parkinson</strong> published "An Essay on the Shaking Palsy," a remarkably accurate description based on just six patients, some of whom he had only observed on the street.<a href="#ref1" class="cite">[1]</a></p>

            <p>He described the "involuntary tremulous motion, with lessened muscular power, in parts not in action... with a propensity to bend the trunk forwards, and to pass from a walking to a running pace."</p>

            <p>Parkinson's careful clinical observation established the condition as a distinct entity. French neurologist <strong>Jean-Martin Charcot</strong> later refined the description in the 1870s, adding rigidity and distinguishing it from other tremor disorders. Charcot named it "Parkinson's disease" in honor of its discoverer.</p>

            <h2>Understanding the Brain</h2>
            <p>The substantia nigra ("black substance") gets its name from the dark pigment in its dopamine-producing neurons. These neurons project to the <strong>striatum</strong>, forming the nigrostriatal pathway crucial for coordinating movement.</p>

            <p>Dopamine acts as a neurotransmitter, modulating the complex circuitry of the basal ganglia. When dopamine is depleted, this circuitry becomes unbalanced, leading to the characteristic motor symptoms.</p>

            <p>The pathological hallmark of Parkinson's is the <strong>Lewy body</strong>, clumps of misfolded alpha-synuclein protein inside neurons. These aggregates spread through the brain in a predictable pattern, explaining why symptoms evolve over time.</p>

            <h2>Causes and Risk Factors</h2>
            <p>Most Parkinson's cases are "idiopathic" (cause unknown). It likely results from a combination of:</p>

            <ul>
                <li><strong>Genetics:</strong> Mutations in genes like LRRK2, SNCA, Parkin increase risk</li>
                <li><strong>Environment:</strong> Pesticide exposure, rural living, well water</li>
                <li><strong>Aging:</strong> The strongest risk factor; rare before age 50</li>
                <li><strong>Protective factors:</strong> Caffeine, smoking (paradoxically), exercise</li>
            </ul>

            <h2>Non-Motor Symptoms</h2>
            <p>Often more disabling than tremor, non-motor symptoms include:</p>

            <ul>
                <li><strong>Depression and anxiety:</strong> Present in ~50% of patients</li>
                <li><strong>Cognitive impairment:</strong> Executive dysfunction; dementia in late stages</li>
                <li><strong>Sleep disorders:</strong> REM sleep behavior disorder, insomnia, daytime sleepiness</li>
                <li><strong>Autonomic dysfunction:</strong> Constipation, urinary issues, orthostatic hypotension</li>
                <li><strong>Hyposmia:</strong> Loss of smell; often precedes motor symptoms by years</li>
            </ul>

            <h2>The Levodopa Revolution (1960s)</h2>
            <p>The discovery of levodopa transformed Parkinson's treatment and stands as one of the great achievements of neurology.</p>

            <p>In the late 1950s, <strong>Oleh Hornykiewicz</strong> in Vienna discovered that dopamine was severely depleted in the brains of deceased Parkinson's patients.<a href="#ref2" class="cite">[2]</a> This suggested replacing dopamine might help.</p>

            <p>Since dopamine can't cross the blood-brain barrier, researchers tried its precursor, <strong>levodopa</strong> (L-DOPA). In 1967, <strong>George Cotzias</strong> demonstrated that high-dose oral levodopa dramatically improved symptoms.<a href="#ref3" class="cite">[3]</a></p>

            <blockquote>
                <p>"Patients who had been wheelchair-bound got up and walked. It was like a miracle."</p>
                <cite>- Oliver Sacks, describing levodopa's effects</cite>
            </blockquote>

            <p>Levodopa remains the most effective treatment, but long-term use leads to complications: motor fluctuations ("wearing off") and dyskinesias (involuntary movements).</p>

            <h2>Modern Treatment</h2>
            <p>Current management combines multiple approaches:</p>

            <h3>Medications</h3>
            <ul>
                <li><strong>Levodopa/carbidopa:</strong> Gold standard; carbidopa prevents peripheral conversion</li>
                <li><strong>Dopamine agonists:</strong> Pramipexole, ropinirole, which directly stimulate dopamine receptors</li>
                <li><strong>MAO-B inhibitors:</strong> Selegiline, rasagiline, which slow dopamine breakdown</li>
                <li><strong>COMT inhibitors:</strong> Entacapone, which extends levodopa's effect</li>
            </ul>

            <h3>Deep Brain Stimulation</h3>
            <p><strong>DBS</strong> involves implanting electrodes in specific brain regions (subthalamic nucleus or globus pallidus) connected to a pacemaker-like device. High-frequency electrical stimulation modulates abnormal brain activity, reducing motor symptoms and allowing medication reduction.</p>

            <p>DBS can dramatically improve quality of life for appropriate candidates, though it doesn't slow disease progression.</p>

            <h2>The Search for Disease-Modifying Treatments</h2>
            <p>Current treatments manage symptoms but don't slow neurodegeneration. Research focuses on:</p>

            <ul>
                <li><strong>Alpha-synuclein targeting:</strong> Antibodies, small molecules to prevent aggregation</li>
                <li><strong>Gene therapy:</strong> Delivering genes to boost dopamine production</li>
                <li><strong>Neuroprotection:</strong> Preserving remaining dopamine neurons</li>
                <li><strong>Cell replacement:</strong> Stem cell-derived dopamine neurons</li>
            </ul>

            <p>Clinical trials are ongoing, but no disease-modifying therapy has yet succeeded.</p>

            <h2>Living with Parkinson's</h2>
            <p>Non-pharmacological approaches are crucial:</p>

            <ul>
                <li><strong>Exercise:</strong> Strong evidence for benefit; may slow progression</li>
                <li><strong>Physical therapy:</strong> Gait training, balance exercises</li>
                <li><strong>Speech therapy:</strong> LSVT LOUD for hypophonia</li>
                <li><strong>Support groups:</strong> Community and shared experience</li>
            </ul>

            <p>With modern treatment, many people with Parkinson's live decades with good quality of life. The disease is serious but not hopeless, and research continues to advance.</p>

            <div class="sources">
                <h2>Sources</h2>
                <ol>
                    <li id="ref1">Parkinson, J. (1817). An Essay on the Shaking Palsy. London: Whittingham and Rowland.</li>
                    <li id="ref2">Hornykiewicz, O. (2006). The discovery of dopamine deficiency in the parkinsonian brain. Journal of Neural Transmission Supplement, (70), 9-15.</li>
                    <li id="ref3">Cotzias, G. C., et al. (1967). Modification of Parkinsonism: chronic treatment with L-dopa. NEJM, 276(7), 374-379.</li>
                    <li id="ref4">Poewe, W., et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.</li>
                    <li id="ref5">Parkinson's Foundation. (2024). Understanding Parkinson's. <a href="https://www.parkinson.org" target="_blank">parkinson.org</a></li>
                </ol>
            </div>
        </article>
    </main>

    <a href="#top" class="back-to-top" title="Back to top">↑</a>

    <footer class="footer">
        <span>Adi Desai 2025</span>
        <span>All opinions are my own</span>
    </footer>
</body>
</html>
